Jazz Pharmaceuticals PLC, established in 2003 and headquartered in Dublin, Ireland, is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases. Their focus lies on oncology (cancer treatment) and neuroscience (treating nervous system disorders), often targeting areas with limited or no existing treatment options. Jazz prioritizes innovation and aims to empower patients by transforming biopharmaceutical discoveries into novel medications.
One of Jazz's most notable products is Xyrem (sodium oxybate), a medication approved by the US Food and Drug Administration (FDA) for treating excessive daytime sleepiness (EDS) in patients with narcolepsy. In 2017, net product sales of Xyrem represented a significant portion of Jazz's total revenue. However, the company has expanded its portfolio in recent years. Successes like Sunosi, a medication approved for treating EDS in both narcolepsy and obstructive sleep apnea, demonstrate their commitment to addressing unmet medical needs. While Sunosi was later acquired by Axsome Therapeutics in 2022, it highlights Jazz's ongoing research and development efforts.
Beyond established products, Jazz boasts a robust pipeline of promising therapies in various stages of development. They are particularly focused on rare, severe childhood-onset epilepsy, aiming to provide novel treatment options for this challenging condition. Their commitment extends beyond oncology and neuroscience; Jazz has also explored treatments for conditions like cholangiocarcinoma, a rare form of bile duct cancer. This diversified approach allows them to potentially improve the lives of a wider range of patients.
The company operates with a patient-centric philosophy. They prioritize understanding the challenges faced by patients and their families. This focus on patient needs fuels their research and development efforts, driving them to create innovative solutions that can truly make a difference. Jazz also actively partners with patient advocacy groups to raise awareness about the conditions they target and ensure patients have access to their medications.